Biocon's Subsidiary Receives EU Panel Nod For Bone Health Biosimilars Vevzuo And Denosumab BBL

Biocon Ltd. has announced that its subsidiary, Biocon Biologics, has received a positive recommendation from the European Medicines Agency's committee for medical products to market its drugs, Vevzuo and Denosumab BBL, in the European Union. The recommendation follows applications submitted by Biosimilar Collaborations Ireland, an indirect wholly-owned subsidiary of Biocon Biologics.

The drugs are biosimilars of Denosumab and are used for bone health. While the committee has given its approval, Biocon Biologics will only be able to market the drugs once the European Commission accepts the recommendation.